215 related articles for article (PubMed ID: 16436342)
1. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream.
Plewig G; Holland KT; Nenoff P
Eur J Dermatol; 2006; 16(1):48-55. PubMed ID: 16436342
[TBL] [Abstract][Full Text] [Related]
2. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne.
Tunca M; Akar A; Ozmen I; Erbil H
Int J Dermatol; 2010 Dec; 49(12):1440-4. PubMed ID: 21091683
[TBL] [Abstract][Full Text] [Related]
3. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study.
Dreno B; Foulc P; Reynaud A; Moyse D; Habert H; Richet H
Eur J Dermatol; 2005; 15(3):152-5. PubMed ID: 15908296
[TBL] [Abstract][Full Text] [Related]
4. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris.
Pazoki-Toroudi H; Nassiri-Kashani M; Tabatabaie H; Ajami M; Habibey R; Shizarpour M; Babakoohi S; Rahshenas M; Firooz A
J Dermatolog Treat; 2010 May; 21(3):212-6. PubMed ID: 20394495
[TBL] [Abstract][Full Text] [Related]
5. Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris.
Takigawa M; Tokura Y; Shimada S; Furukawa F; Noguchi N; Ito T;
J Dermatol; 2013 Aug; 40(8):620-5. PubMed ID: 23724808
[TBL] [Abstract][Full Text] [Related]
6. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria.
Eady EA; Bojar RA; Jones CE; Cove JH; Holland KT; Cunliffe WJ
Br J Dermatol; 1996 Jan; 134(1):107-13. PubMed ID: 8745894
[TBL] [Abstract][Full Text] [Related]
7. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea.
McHugh RC; Rice A; Sangha ND; McCarty MA; Utterback R; Rohrback JM; Osborne BE; Fleischer AB; Feldman SR
J Dermatolog Treat; 2004 Sep; 15(5):295-302. PubMed ID: 15370397
[TBL] [Abstract][Full Text] [Related]
8. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
[TBL] [Abstract][Full Text] [Related]
9. Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents.
Wilhelm KP; Wilhelm D; Neumeister C; Zsolt I; Schwantes U
Clin Exp Dermatol; 2012 Mar; 37(2):112-7. PubMed ID: 22103435
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients.
Jung JY; Kwon HH; Yeom KB; Yoon MY; Suh DH
Int J Dermatol; 2011 Mar; 50(3):350-7. PubMed ID: 21342170
[TBL] [Abstract][Full Text] [Related]
11. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin.
Bojar RA; Hittel N; Cunliffe WJ; Holland KT
Drugs; 1995; 49 Suppl 2():164-7. PubMed ID: 8549289
[No Abstract] [Full Text] [Related]
12. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.
Jacobs MR; Appelbaum PC
Expert Opin Pharmacother; 2006 Oct; 7(14):1957-66. PubMed ID: 17020421
[TBL] [Abstract][Full Text] [Related]
13. Comparison of chloroxylenol 0.5% plus salicylic acid 2% cream and benzoyl peroxide 5% gel in the treatment of acne vulgaris: a randomized double-blind study.
Boutli F; Zioga M; Koussidou T; Ioannides D; Mourellou O
Drugs Exp Clin Res; 2003; 29(3):101-5. PubMed ID: 14708455
[TBL] [Abstract][Full Text] [Related]
14. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes.
Kuwahara K; Kitazawa T; Kitagaki H; Tsukamoto T; Kikuchi M
J Dermatol Sci; 2005 Apr; 38(1):47-55. PubMed ID: 15795123
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents.
Nishijima S; Kurokawa I; Kawabata S
J Int Med Res; 1996; 24(6):473-7. PubMed ID: 8959531
[TBL] [Abstract][Full Text] [Related]
16. Erythromycin-resistance of cutaneous bacterial flora in acne.
Dreno B; Reynaud A; Moyse D; Habert H; Richet H
Eur J Dermatol; 2001; 11(6):549-53. PubMed ID: 11701406
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment.
Kumar A; Agarwal SP; Ahuja A; Ali J; Choudhry R; Baboota S
Pharmazie; 2011 Feb; 66(2):111-4. PubMed ID: 21434572
[TBL] [Abstract][Full Text] [Related]
18. Contribution to the interpretation of the occurrence of unsuccessful therapeutical results in acne vulgaris with topical erythromycin (Propionibact. acnes).
Gloor M; Lamerz A; Franke-Hoffman M
Zentralbl Bakteriol A; 1981 Feb; 248(4):502-8. PubMed ID: 6452774
[TBL] [Abstract][Full Text] [Related]
19. [Double-blind group comparison of topical meclocycline, erythromycin and placebo in the treatment of papulo-pustulosa acne].
Rozman TA; Klövekorn G; Kompa H
Z Hautkr; 1984 Dec; 59(23):1623-34. PubMed ID: 6240840
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany.
Alba V; Urban E; Angeles Dominguez M; Nagy E; Nord CE; Palacín C; Vila J
Int J Antimicrob Agents; 2009 Mar; 33(3):272-5. PubMed ID: 19095414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
